Introduction: Social media continues to grow in size, and popularity, The prevalence of social networking continues to develop and will likely play an increasing role in all aspects of society and business, including in healthcare services. This rapid growth has directly influenced healthcare professionals in the clinical setting. Aim: To assess the perceptions and usage of SM (SM) by OSs (OS) in Jeddah, Saudi Arabia, and its impact on their profession, and to evaluate their level of awareness of the potential risks on their practice. Methods: Quantitative: A cross-sectional survey was distributed to practicing OSs in 15 healthcare centers in Jeddah, Saudi Arabia (μ=323) using convenience sampling. Data was analyzed using SPSS. Qualitative: Eight OSs were recruited by purposive and snowball sampling and interviewed using a semi-structured approach. Data was analyzed using thematic content analysis. Results: The Quantitative survey revealed that 165 OSs participated (RR=51%). OSs who use SM partly or entirely for professional purposes represent 53.7% (n=87). The remaining OSs were excluded. Virtually 90% were 40 years old or younger. Residents were less likely to reply to medical questions on SM (p=0.035). It was found that 74.7% of OSs use SM daily. The most commonly used platform was Twitter (75.9%), with Instagram and Snapchat being significantly more used by younger OSs (p= 0.013 and 0.003, respectively). The results of the Qualitative interviews revealed four themes: Guidelines, Ethics and Professionalism; Usage and Perceptions; Doctor-Patient Relationship; Quality of Online Content. Conclusion: OSs’ perceptions and usage were generally cautious. The major concerns were patient confidentiality, along with ethical and legal consequences. The need to contribute to quality online content was evident. Lack of formal guidelines was a continuous theme. The development of national guidelines on SM use in the orthopaedic profession is recommended.

Gamma-glutamylcysteine ethyl ester (GCEE) is a precursor of glutathione (GSH) with promising hepatoprotective effects. This investigation aimed to evaluate the hepatoprotective effects of GCEE against cyclophosphamide- (CP-) induced toxicity, pointing to the possible role of peroxisome proliferator activated receptor gamma (PPARγ). Wistar rats were given GCEE two weeks prior to CP. Five days after CP administration, animals were sacrificed and samples were collected. Pretreatment with GCEE significantly alleviated CP-induced liver injury by reducing serum aminotransferases, increasing albumin, and preventing histopathological and hematological alterations. GCEE suppressed lipid peroxidation and nitric oxide production and restored GSH and enzymatic antioxidants in the liver, which were associated with downregulation of COX-2, iNOS, and NF-κB. In addition, CP administration significantly increased serum proinflammatory cytokines and the expression of liver caspase-3 and BAX, an effect that was reversed by GCEE. CP-induced rats showed significant downregulation of PPARγ which was markedly upregulated by GCEE treatment. These data demonstrated that pretreatment with GCEE protected against CP-induced hepatotoxicity, possibly by activating PPARγ, preventing GSH depletion, and attenuating oxidative stress, inflammation, and apoptosis. Our findings point to the role of PPARγ and suggest that GCEE might be a promising agent for the prevention of CP-induced liver injury.

Background To date, there are insufficient data on long-term outcomes of weight loss surgery in children and adolescents with obesity beyond 5 years of follow-up. This study aimed to analyze durability of weight loss and comorbidity resolution, growth velocity, and adverse events associated with laparoscopic sleeve gastrectomy (LSG) in children and adolescents with severe obesity. Study Design In this prospective cohort study, 2,504 children and adolescents with class II/III obesity who were enrolled in a multidisciplinary, family-based pediatric obesity management program underwent LSG between 2008 and 2021. Weight loss, growth, comorbidity resolution, and adverse event data during the first 10 years after LSG were analyzed. Results The cohort age was 5 to 21 years at the time of operation, and 55% were female. Mean ± SD percentage of excess weight lost during short- (1 to 3 years; n = 2,051), medium- (4 to 6 years; n = 1,268), and long-term (7 to 10 years; n = 632) follow-up was 82.3% ± 20.5%, 76.3% ± 29.1%, and 71.1% ± 26.9%, respectively. Complete comorbidity remission at long-term follow-up was observed in 74%, 59%, and 64% of type 2 diabetes, dyslipidemia, and hypertension cases, respectively. Mean ± SD height z-score change at short-, medium-, and long-term follow-up was 0.1 ± 0.5, 0.1 ± 1.2, and 0.0 ± 0.8, respectively, representing no significant change in growth velocity. There were 27 adverse events (1%) with no procedure-related mortality. Conclusions Long-term follow-up after LSG in children and adolescents demonstrates durable weight loss, maintained comorbidity resolution, and unaltered growth. Visual Abstract

No abstract